GeNeuro SA - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 24 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

GeNeuro SA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'GeNeuro SA - Product Pipeline Review - 2014', provides an overview of the GeNeuro SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GeNeuro SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of GeNeuro SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of GeNeuro SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the GeNeuro SA's pipeline products

Reasons to buy

- Evaluate GeNeuro SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of GeNeuro SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the GeNeuro SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of GeNeuro SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of GeNeuro SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of GeNeuro SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
GeNeuro SA Snapshot 4
GeNeuro SA Overview 4
Key Information 4
Key Facts 4
GeNeuro SA - Research and Development Overview 5
Key Therapeutic Areas 5
GeNeuro SA - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
GeNeuro SA - Pipeline Products Glance 9
GeNeuro SA - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
GeNeuro SA - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
GeNeuro SA - Drug Profiles 13
GNbAC-1 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Monoclonal Antibody for CIDP 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
GNbAC-2 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Monoclonal Antibody for Diabetes 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
GeNeuro SA - Pipeline Analysis 18
GeNeuro SA - Pipeline Products by Target 18
GeNeuro SA - Pipeline Products by Route of Administration 19
GeNeuro SA - Pipeline Products by Molecule Type 20
GeNeuro SA - Recent Pipeline Updates 21
GeNeuro SA - Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24

List of Tables
GeNeuro SA, Key Information 4
GeNeuro SA, Key Facts 4
GeNeuro SA - Pipeline by Indication, 2014 6
GeNeuro SA - Pipeline by Stage of Development, 2014 7
GeNeuro SA - Monotherapy Products in Pipeline, 2014 8
GeNeuro SA - Phase II, 2014 9
GeNeuro SA - Phase I, 2014 10
GeNeuro SA - Preclinical, 2014 11
GeNeuro SA - Discovery, 2014 12
GeNeuro SA - Pipeline by Target, 2014 18
GeNeuro SA - Pipeline by Route of Administration, 2014 19
GeNeuro SA - Pipeline by Molecule Type, 2014 20
GeNeuro SA - Recent Pipeline Updates, 2014 21
GeNeuro SA, Subsidiaries 22